Skip to Content
Merck
CN
  • Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia.

Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia.

Human molecular genetics (2014-05-23)
Sander M Houten, Simone Denis, Heleen Te Brinke, Aldo Jongejan, Antoine H C van Kampen, Edward J Bradley, Frank Baas, Raoul C M Hennekam, David S Millington, Sarah P Young, Dianne M Frazier, Muge Gucsavas-Calikoglu, Ronald J A Wanders
ABSTRACT

Dienoyl-CoA reductase (DECR) deficiency with hyperlysinemia is a rare disorder affecting the metabolism of polyunsaturated fatty acids and lysine. The molecular basis of this condition is currently unknown. We describe a new case with failure to thrive, developmental delay, lactic acidosis and severe encephalopathy suggestive of a mitochondrial disorder. Exome sequencing revealed a causal mutation in NADK2. NADK2 encodes the mitochondrial NAD kinase, which is crucial for NADP biosynthesis evidenced by decreased mitochondrial NADP(H) levels in patient fibroblasts. DECR and also the first step in lysine degradation are performed by NADP-dependent oxidoreductases explaining their in vivo deficiency. DECR activity was also deficient in lysates of patient fibroblasts and could only be rescued by transfecting patient cells with functional NADK2. Thus NADPH is not only crucial as a cosubstrate, but can also act as a molecular chaperone that activates and stabilizes enzymes. In addition to polyunsaturated fatty acid oxidation and lysine degradation, NADPH also plays a role in various other mitochondrial processes. We found decreased oxygen consumption and increased extracellular acidification in patient fibroblasts, which may explain why the disease course is consistent with clinical criteria for a mitochondrial disorder. We conclude that DECR deficiency with hyperlysinemia is caused by mitochondrial NADP(H) deficiency due to a mutation in NADK2.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-AASS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab3
Sigma-Aldrich
BIS-TRIS, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
BIS-TRIS, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
BIS-TRIS, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
BIS-TRIS, ≥98.0% (titration)
SAFC
BIS-TRIS
Thioctic acid for system suitability, European Pharmacopoeia (EP) Reference Standard
Thioctic acid containing impurity B, European Pharmacopoeia (EP) Reference Standard
Thioctic acid, European Pharmacopoeia (EP) Reference Standard
USP
Alpha Lipoic Acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Anti-Lipoic Acid Rabbit pAb, liquid, Calbiochem®
SAFC
BIS-TRIS
Sigma-Aldrich
BIS-TRIS, Vetec, reagent grade, ≥98%, RNase and DNase free
Sigma-Aldrich
(±)-α-Lipoic acid, ≥98.0%
Sigma-Aldrich
(±)-α-Lipoic acid, synthetic, ≥99% (titration), powder
Sigma-Aldrich
(±)-α-Lipoic acid, suitable for cell culture, BioReagent, ≥99%